IHS Chemical Week

People & Business :: Companies

Ranbaxy Drops Out of Battle for Merck KGaA’s Generics Unit

1:43 PM MDT | March 28, 2007 | Deepti Ramesh

The largest pharma company in India, Ranbaxy Laboratories (Gurgaon) has dropped out of the second round of bidding for German pharma major, Merck KGaA’s generics business unit, according to a series of unconfirmed media reports at CW press time last week. The other companies believed to still be in the race for the generic unit are Teva Pharmaceuticals (Petach Tikva, Israel), Actavis (Reykjavik, Iceland), and Mylan Laboratories (Pittsburgh). The estimated worth of Merck’s generics business is around $6 billion, industry sources say. Ranbaxy declined...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa